Results 91 to 100 of about 7,770 (204)

What role for real-world evidence in market access of biosimilars?

open access: yesFrontiers in Pharmacology
Experience with the use of biosimilars in real-life practice provides an excellent opportunity to collect real-world evidence aimed at addressing residual uncertainties about biosimilars.
Steven Simoens   +2 more
doaj   +1 more source

Inflammatory Bowel Disease: Mechanisms and Therapeutic Advances

open access: yesMedComm, Volume 7, Issue 9, September 2026.
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a rising, multifactorial chronic disorder driven by dysregulated mucosal immunity in genetically susceptible individuals and influenced by environmental and microbial factors.
Andrea Papait   +5 more
wiley   +1 more source

Anti-Adalimumab Antibodies Purified from Juvenile Idiopathic Arthritis Patients: Kinetic Characterization Among Biosimilars

open access: yesBiosensors
The use of adalimumab biosimilars has become increasingly common in clinical practice, reflecting their growing acceptance and efficacy as therapeutic alternatives to reference biologics.
Andrea Di Santo   +8 more
doaj   +1 more source

Semaglutide Injection Once‐Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active‐Controlled Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8602-8612, September 2026.
ABSTRACT Aim To evaluate and compare the efficacy, safety, and immunogenicity of a synthetic semaglutide injection (Test semaglutide) with Wegovy (Reference semaglutide) injection for weight management. Materials and Methods This randomized, Phase III, non‐inferiority study included adults with obesity or overweight with or without comorbidities from ...
Unnikrishnan Ambika Gopalakrishnan   +26 more
wiley   +1 more source

Reorganization of public procurement of biosimilars and its economic effect on the monoclonal antibody market in Russia

open access: yesФармакоэкономика
Background. The increasing number of registered biosimilars of monoclonal antibodies (mAbs) is altering the structure of the pharmaceutical market by amplifying the share of domestic manufacturers.
A. Yu. Efremov   +5 more
doaj   +1 more source

Optimizing safety and efficacy of asparaginase and blinatumomab therapy in frontline acute lymphoblastic leukemia regimens in diverse health care settings—international expert consensus

open access: yesCancer, Volume 132, Issue 16, 15 August 2026.
ABSTRACT Frontline blinatumomab combined with chemotherapy has resulted in improved outcomes in both pediatric and adult patients with acute lymphoblastic leukemia and is considered the new cornerstone of acute lymphoblastic leukemia treatment. The role of asparaginase in this new landscape of acute lymphoblastic leukemia treatment was extensively ...
Daniel J. DeAngelo   +15 more
wiley   +1 more source

Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19.

open access: yesPLoS ONE
ObjectiveTo evaluate the impact of the entry of biosimilars on the pricing of eight biologic products in 57 countries and regions.MethodsWe utilized an interrupted time series design and IQVIA MIDAS® data to analyze the annual sales data of eight ...
Hui-Han Chen   +2 more
doaj   +1 more source

Biosimilar Rituximab in ANCA‐Associated Vasculitis Compared to the Originator: A Multicenter Cohort Study

open access: yesACR Open Rheumatology, Volume 8, Issue 8, August 2026.
Objective To evaluate the six‐month effectiveness and safety of rituximab biosimilars compared to the originator in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and outcomes following originator to biosimilar switching. Methods We recruited adults with GPA or MPA treated with the rituximab originator or a biosimilar for ...
Arielle Mendel   +14 more
wiley   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

open access: yesArthritis &Rheumatology, Volume 78, Issue 8, Page 1674-1686, August 2026.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie   +12 more
wiley   +1 more source

Fostering medication review competence of pharmacy students: An assessment by students and their preceptors after advanced‐level practical internship

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2549-2560, August 2026.
Aims The aim of this study was to introduce a new assessment method for pharmacy students' real‐life competence in reviewing medications after obligatory advanced‐level practical internship in Finland. Methods The new medication review (MR) competence assessment method consisted of (1) a self‐assessment by pharmacy students and (2) a performance ...
Katja Leiman   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy